Formulary Search

You are here : Home > Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Return to the search options.

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Wet age-related macular degeneration (Bevacizumab - Wet age-related macular degeneration)

Records returned : 6 (on 04 Sep 2025 at 05:03:58). Return to search results for ' Wet age-related macular degeneration '.

Show Icon and Status Keys Hide Icon and Status Keys

Icon Key

NFD1

Non formulary

NFD2

Not assessed for formulary status. Apply to APC / DTC before use.

Controlled drug. Prescribing and/or storage requirements may apply

Restrictions apply

Safety Alert

Unlicensed - no UK marketing license in place

Off Label

Not licensed for this indication.

NHSE

Treatment commissioned by NHS England

CDF

Cancer Drugs Fund

ICB

Treatment commissioned by the ICB

BlueTeq form to be completed

NICE

Link to the NICE website

Low carbon device

SPC

View the treatment summary for {padindicationname} on https://www.medicines.org.uk

Status Key

Red

Specialist ONLY drugs - treatment initiated and continued by specialist clinicians

Amber

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care under a formal shared care agreement

Green

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing.

Green (see narrative)

GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiation and continuation of prescribing. Please refer to the narrative on the Drug Profile page where additional information may be conveyed as to the place in therapy or restrictions for use that have been locally agreed.

Non Formulary

Not recommended for use in any health setting across the Surrey Heartlands Integrated Care System

Blue

Prescribing initiated and stabilised by specialist but has potential to transfer to primary care WITHOUT a formal shared care agreement. Please note that in some circumstances a specialist may recommend that prescribing can be started in primary care.

See narrative

See narrative - may be applied in instances where a traffic light status has not yet been agreed but an entry to the formulary has been made to clarify interim arrangements.

Drug

Indication

Status

Restrictions/Comments

Formulary Status

Links

1. Bevacizumab

Drug:

Bevacizumab

Indication :

Wet age-related macular degeneration

Status :

Non Formulary

Formulations :

Intravitreal injection

Restrictions / Comments:

Important

Avastin is not supported for use in wet AMD

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :

Guidelines

NFD1

Off Label

SPC

2. Aflibercept

Drug:

Aflibercept

Indication :

Wet age-related macular degeneration

Status :

Red

Formulations :

Not Specified

Restrictions / Comments:

Important

Aflibercept 2mg (biosimilar when available) remains a first line treatment option (alongside ranibizumab biosimilar). Aflibercept 8mg can be used in those patients that have not responded sufficiently to the 2mg treat and extend protocols and that aflibercept 8mg will be used no more frequently than every 8 weeks in line with the licence

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Links :